The (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation (HBVr) in patients on immunosuppressive ...

Breakthrough therapy designation recognises the potential of brelovitug to transform the lives of people living with CHD. We ...

Breakthrough Therapy Designation is designed to expedite the development and review of therapies that may show significant ...

Preterm babies who receive a hepatitis B virus (HBV) vaccine at birth aren't at increased risk of developing a chronic lung disease that affects ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

US FDA grants breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for treatment of chronic hepatitis delta: Redwood City, California Thursday, January 23, 2025, ...

Patients with HIV and hepatitis B coinfection are at an increased risk for hepatitis D, which is associated with an increased ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

Privately-held US biopharma Bluejay Therapeutics has announced that its lead product candidate brelovitug—also known as BJT-778—has received US Food and Drug Administration Breakthrough Therapy ...

Arbutus Biopharma (ABUS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from ...